Interleukin-23 drives innate and T cell–mediated intestinal inflammation (original) (raw)

Skip Nav Destination

Article| October 09 2006

Sophie Hue,

1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, England, UK

Search for other works by this author on:

Philip Ahern,

1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, England, UK

Search for other works by this author on:

Sofia Buonocore,

1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, England, UK

Search for other works by this author on:

Marika C. Kullberg,

2Immunology and Infection Unit, Department of Biology, University of York and The Hull York Medical School, York YO10 5YW, England, UK

Search for other works by this author on:

Daniel J. Cua,

3Department of Discovery Research, Schering-Plough Biopharma, Palo Alto, CA 94304

Search for other works by this author on:

Brent S. McKenzie,

3Department of Discovery Research, Schering-Plough Biopharma, Palo Alto, CA 94304

Search for other works by this author on:

Fiona Powrie,

1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, England, UK

Search for other works by this author on:

Kevin J. Maloy

1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, England, UK

Search for other works by this author on:

Crossmark: Check for Updates

Sophie Hue

1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, England, UK

Philip Ahern

1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, England, UK

Sofia Buonocore

1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, England, UK

Marika C. Kullberg

2Immunology and Infection Unit, Department of Biology, University of York and The Hull York Medical School, York YO10 5YW, England, UK

Daniel J. Cua

3Department of Discovery Research, Schering-Plough Biopharma, Palo Alto, CA 94304

Brent S. McKenzie

3Department of Discovery Research, Schering-Plough Biopharma, Palo Alto, CA 94304

Fiona Powrie

1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, England, UK

Kevin J. Maloy

1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, England, UK

Abbreviations used: CD, Crohn's disease; IBD, inflammatory bowel disease; FSC, forward scatter; KC, mouse chemokine CXCL1; LPL, lamina propria leukocyte; MCP-1, monocyte chemoattractant protein–1; MLN, mesenteric LN; Q-PCR, quantitative PCR; SSC, side scatter.

Received: May 22 2006

Accepted: September 13 2006

Online ISSN: 1540-9538

Print ISSN: 0022-1007

The Rockefeller University Press

2006

J Exp Med (2006) 203 (11): 2473–2483.

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract involving aberrant activation of innate and adaptive immune responses. We have used two complementary models of IBD to examine the roles of interleukin (IL)-12 family cytokines in bacterially induced intestinal inflammation. Our results clearly show that IL-23, but not IL-12, is essential for the induction of chronic intestinal inflammation mediated by innate or adaptive immune mechanisms. Depletion of IL-23 was associated with decreased proinflammatory responses in the intestine but had little impact on systemic T cell inflammatory responses. These results newly identify IL-23 as a driver of innate immune pathology in the intestine and suggest that selective targeting of IL-23 represents an attractive therapeutic approach in human IBD.

The Rockefeller University Press

2006

You do not currently have access to this content.

Sign in

Client Account

You could not be signed in. Please check your email address / username and password and try again.

Username (Note: This may be your email address.) ?

Password

Could not validate captcha. Please try again.

25,861 Views

674 Web of Science

Suggested Content

See also

Email alerts